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A B S T R A C T
Infectious diseases have always been a major cause of mobility and mortality, early and accurate
diagnosis is important for their management. However, current clinical diagnosis for bacterial infection
still remains troublesome. Recently, many attempts on molecular imaging have been made for prompt
bacteria detection, especially for early and precise disease diagnosis. Among them, maltohexaose-based
probes serve as a superb candidate due to the bacteria-specific maltodextrin transport pathway. These
probes can visualize bacterial foci with unparalleled sensitivity and specificity. Such metabolism-based
targeting strategy offers a powerful delivery platform for imaging and theranostic agents, providing
good translational potential for developing antibacterial agents.
© 2019 Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences.
Published by Elsevier B.V. All rights reserved.
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journal homepa ge: www.elsevier .com/ locate /cc le tInfectious disease is one of the highest causes of morbidity
and mortality in human history. Current golden standard for
diagnosing infection relies on conventional means, such as tissue
biopsies, microbiological culture, urine and blood test [1].
However, these methods are only valid when patients are at
late-stage of infection. It is imperative to develop new powerful
tools for sensitive and specific bacterial detection [2]. Molecular
imaging has been widely researched to precisely diagnose
diseases [3,4]. It shows pathological progress in cellular or even
molecular level, by providing unparalleled sensitivity for early
diagnosis, and therefore serves as a promising tool for early-stage
infection diagnosis [5,6].
67Ga-citrate, 18F-fluorodeoxyglucose (18FDG) and radiolabeled
leukocytes have been approved as clinic tracers for bacterial
infection imaging, and provide good sensitivity for early-stage
diagnosis [7]. Unfortunately, these clinic tracers are not able to
specifically recognize bacteria [8]. In order to improve this, many
attempts were made to develop new targets for bacterial
infections, including antibiotics, antibacterial peptide, antibodies,
metabolizable compounds and ligands, and others [9–12]. Among* Corresponding author at: State Key Laboratory of Molecular Vaccinology and
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translational potential, Chin. Chem. Lett. (2019), https://doi.org/10.1016these targeting strategies, bacteria-specific metabolism pathway
attracted great interests. Unlike mammalian cells, bacteria have
their own specific pathway for nutrients metabolism, such as sugar
metabolism based on maltodextrin transporter system [13]. This
system is also found to be implicated in the virulence mechanisms
of some of these pathogens and prove to be absent in mammalian
cell, making it promising for bacteria targeting [14].
The maltodextrin transporter belongs to adenosine triphos-
phate (ATP)–binding cassette (ABC) family of transporters, it has
been shown to be present in many bacterial species, both gram-
positive and gram-negative [15]. For bacteria, maltodextrin
transporters in the surface can recognize non-reducing end of
maltohexaose, and internalize imaging agents conjugated to
maltohexaose [16]. These probes can selectively enter pathogenic
bacteria cells through maltodextrin transporter induced internali-
zation, and provide unambiguous imaging signal for diagnostic
purpose, moreover, glucose oligomers in maltohexaose structure
allow these compounds bypass the lumen of intestinal tissues and
the skin outer layers, resulting in little accumulation of normal
flora, so that imaging sensitivity is guaranteed [17]. All these traits
make it potential to translating maltohexaose-based probes into
clinical use.
Maltodextrin-based imaging probes (MDPs) were first reported
in 2011, for in vitro and in vivo bacteria detection. In this work,
alkyne-functionalized fluorescent dyes perylene and IR786 were
clicked onto an azide-functionalized maltohexaose at the modifi-
cation-tolerable reducing end [18]. It is verified that MDPs can
specifically and selectively accumulate in bacterial infection site,Academy of Medical Sciences. Published by Elsevier B.V. All rights reserved.
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infection. The experiment results also confirmed the targeting
mechanism as active maltodextrin-transporter pathway, which
is consistent with former hypothesis. Besides the capacity of
detecting bacterial biofilm and discriminating bacterial lesion
from sterile inflammation, MDPs are also capable of imaging
Escherichia coli (E. coli) microflora as few as 105 colony-forming
units (CFU) in vivo, whose sensitivity is two orders of magnitude
higher compared with many peer probes. This work efficiently
settled the interference we former talked about, and gives a
precisely diagnostic result.
Unfortunately, as fluorescent probes, MDPs still suffers from
some short-comings of fluorescent imaging, particularly the poor
tissue penetration of light. To address this issue, 18F-labeled
maltohexaose (MH18F) was introduced as a positron emission
tomography (PET) tracer for acute diagnosis of bacterial infection
[19]. MH18F was compared with 18FDG for E. coli imaging in rats,
and generated 30-fold signal to noise ratio between infected versus
healthy tissue, while 18FDG only achieved 1.5-fold. Besides the
excellent targeting ability, MH18F has promising potential in
identifying bacterial drug resistance. Maltodextrin transports are
ATP-binding cassette (ABC) transporters, in other words, the
process of maltohexaose substrates internalization, like MH18F,
has close connection with cellular metabolism and bacterial
viability, and the results showed that MH18F could identify drug
resistance of bacteria and measure the efficacy of antibiotic
therapy. This striking result indicates that MH18F might be a good
candidate for guiding the antibiotics selection.
It is lucky that we may find a way to precisely detect bacterial
infection, but the cure still remains intractable, especially when
facing the multi-drug resistant strains. We need treatments that
immediately and directly attack bacteria with little chance to
induce drug resistance, fortunately nano-theranostics offers a
feasible solution to this [20]. By combination of diagnostic imaging
with anti-bacterial therapy, the nano-formula purpurin 18-loaded
nanoliposome (MLP18) has potent efficacy in labelling and fighting
methicillin-resistant Staphylococcus aureus (MRSA) [21]. The
purpurin 18 payload in MLP18 is an excellent fluorescence
imaging/photoacoustic imaging (FLI/PAI) probe, as well as excel-
lent sono-sensitizer. This makes MLP18 able to accomplish precise
bacteria detection following by instant sono-dynamic therapy
(SDT). Unlike nucler tracers hampered by their short life and
radiation risk, MLP18 can be used to monitor infection progress
with longer period and for multiple times, while its signal of near-
infrared FL and PA can overcome tissue absorption and scattering
[22]. With multi-model imaging guidance, bacterial foci can be
well located so that ultrasound irradiation can be applied at the
infection site to activate purpurin 18 and generate singlet oxygen.
After SDT treatment, the integrity of bacterial membrane was
disrupted, and the cell walls were wrinkle and lysed withPlease cite this article in press as: Y. Cheng, et al., Maltohexaose-based p
translational potential, Chin. Chem. Lett. (2019), https://doi.org/10.1016intracellular content leakage. This lethal effect was broad-
spectrum and has no concern of drug-resistance.
In the age of post-antibiotics era, early diagnosis is an effective
mean to alleviate the burden caused by drug resistance in public
health [23,24]. Maltohexaose-based probe was well proven to be
specific and sensitive for targeting bacterial infection, while its
implication with bacterial virulence adds to the use for differentiat-
ing drug-resistant strains. This strategy holds good promise for
developing new contrast agent to diagnose bacterial infection.
However, looking backtothosealreadyapproveddrugs, there isstilla
long way to go before maltohexaose-based probes can enterclinic. At
the same time, lots of different targeting mechanisms and probes are
undergoing preclinical research for early and accurate diagnosis,
such as siderophores and bacterial antibody, it is hopeful that human
canwinthe battle againstdrug resistance bycombination of effective
prevention, precise diagnosis and prompt treatment.
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